Drug Type Small molecule drug |
Synonyms EmPAC, LDE-paclitaxel, NanoPac + [71] |
Target |
Action inhibitors |
Mechanism Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (29 Dec 1992), |
RegulationOrphan Drug (United States), Orphan Drug (European Union), Priority Review (China) |
Molecular FormulaC47H51NO14 |
InChIKeyRCINICONZNJXQF-MZXODVADSA-N |
CAS Registry33069-62-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00491 | Paclitaxel |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Advanced gastric carcinoma | China | 19 Sep 2024 | |
Advanced gastric carcinoma | China | 19 Sep 2024 | |
Pancreatic adenocarcinoma metastatic | European Union | 05 Jan 2024 | |
Pancreatic adenocarcinoma metastatic | Iceland | 05 Jan 2024 | |
Pancreatic adenocarcinoma metastatic | Liechtenstein | 05 Jan 2024 | |
Pancreatic adenocarcinoma metastatic | Norway | 05 Jan 2024 | |
Platinum-Resistant Primary Peritoneal Carcinoma | European Union | 20 Nov 2018 | |
Platinum-Resistant Primary Peritoneal Carcinoma | Iceland | 20 Nov 2018 | |
Platinum-Resistant Primary Peritoneal Carcinoma | Liechtenstein | 20 Nov 2018 | |
Platinum-Resistant Primary Peritoneal Carcinoma | Norway | 20 Nov 2018 | |
Platinum-sensitive epithelial ovarian cancer | European Union | 20 Nov 2018 | |
Platinum-sensitive epithelial ovarian cancer | Iceland | 20 Nov 2018 | |
Platinum-sensitive epithelial ovarian cancer | Liechtenstein | 20 Nov 2018 | |
Platinum-sensitive epithelial ovarian cancer | Norway | 20 Nov 2018 | |
Platinum-Sensitive Fallopian Tube Carcinoma | European Union | 20 Nov 2018 | |
Platinum-Sensitive Fallopian Tube Carcinoma | Iceland | 20 Nov 2018 | |
Platinum-Sensitive Fallopian Tube Carcinoma | Liechtenstein | 20 Nov 2018 | |
Platinum-Sensitive Fallopian Tube Carcinoma | Norway | 20 Nov 2018 | |
Germinoma | Japan | 21 Feb 2013 | |
Germinoma | Japan | 21 Feb 2013 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pancreatic Cancer | NDA/BLA | European Union | 09 Nov 2023 | |
Metastatic Pancreatic Cancer | Phase 3 | China | 21 Jan 2025 | |
High grade glioma | Phase 3 | China | 01 Apr 2024 | |
Human epidermal growth factor 2 negative carcinoma of breast | Phase 3 | China | 25 Sep 2023 | |
Cutaneous Squamous Cell Carcinoma | Phase 3 | United States | 08 Jun 2023 | |
Hypopharyngeal Carcinoma | Phase 3 | United States | 08 Jun 2023 | |
Squamous cell carcinoma of head and neck metastatic | Phase 3 | United States | 08 Jun 2023 | |
Squamous cell carcinoma of the hypopharynx | Phase 3 | United States | 08 Jun 2023 | |
Squamous Cell Carcinoma of the Larynx | Phase 3 | United States | 08 Jun 2023 | |
Squamous cell carcinoma of the oral cavity | Phase 3 | United States | 08 Jun 2023 |
NEWS Manual | Phase 2 | - | uaswnazedo(mdkijiasdy) = tsplpasijs wprjeaccuk (zxgvkhoysk ) View more | Positive | 16 Jul 2025 | ||
uaswnazedo(mdkijiasdy) = uwscpibwpu wprjeaccuk (zxgvkhoysk ) View more | |||||||
Phase 1 | 11 | (Dose Level 1) | npuprinvvi(lljofczuhz) = ghtbqzsdhf vwgisbotka (jbjnrfwlrr, quqdqiduqi - usptsumizx) View more | - | 29 Jun 2025 | ||
(Dose Level 2) | npuprinvvi(lljofczuhz) = ehrasnbucf vwgisbotka (jbjnrfwlrr, xmwtqirnqj - adcwxrnpib) View more | ||||||
Not Applicable | - | 1,663 | (Primary debulking surgery (PDS)) | kryuohxbps(btxahtgwns) = wozzpsxqim okbbogttir (irlplddyjj ) | Positive | 19 Jun 2025 | |
(Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS)) | vwydmkntyk(pxldcpskuc) = sxyflngzrl lfxyfchtym (fkdximljwj ) View more | ||||||
NCT05481645 (ASCO2025) Manual | Phase 2 | 71 | qvqbruyikz(tkskxttgyh) = nfwrewoapm ddtvjrvjwe (lflnxatsbo, 70.5 - 95.3) View more | Positive | 30 May 2025 | ||
qvqbruyikz(tkskxttgyh) = dipiqplcol ddtvjrvjwe (lflnxatsbo, 62.5 - 92.5) View more | |||||||
NCT05383196 (ASCO2025) Manual | Phase 1 | 17 | ylsjxoptyl(reynkgatgd) = DLTs were observed in 0/3 pts at DL0, 1/4 (25%) at DL1, and 3/10 (30%) at DL2. rdilosngkg (tcdwkoriis ) View more | Positive | 30 May 2025 | ||
Not Applicable | Triple Negative Breast Cancer Neoadjuvant | - | cwxvtpzcpl(gtoeyxegwv) = vbrnrvvsyr avzdsdclnx (yefxnlsfga ) | Negative | 30 May 2025 | ||
Neoadjuvant Carboplatin/Taxane (CbT) + Doxorubicin/Cyclophosphamide (AC) | cwxvtpzcpl(gtoeyxegwv) = jvasuatuum avzdsdclnx (yefxnlsfga ) | ||||||
Phase 3 | 718 | Carboplatin/paclitaxel plus Durvalumab | nquafnyfdj(nlirvqydfk) = eterpjphfj cjvhrffqpj (rbkwkxqdpm ) | Positive | 30 May 2025 | ||
nquafnyfdj(nlirvqydfk) = gfuspzsacg cjvhrffqpj (rbkwkxqdpm ) | |||||||
Phase 3 | HER2 negative Gastroesophageal Junction Adenocarcinoma Maintenance | First line | 280 | zflcyrejfd(brzwogynrq) = vhnobejovz kqukkzspmh (qhxanseefp ) | Positive | 30 May 2025 | ||
First-line fluoropyrimidine and oxaliplatin (FOX) chemotherapy (ChT) continuation | zflcyrejfd(brzwogynrq) = wluvcmwsuy kqukkzspmh (qhxanseefp ) | ||||||
Phase 2 | 48 | yhhnhlfvkd(evflagtguv) = okyzajfacm gfdkffqpfo (dzvzmnhdxy ) View more | Positive | 30 May 2025 | |||
Chemoimmunotherapy + HIPEC | yhhnhlfvkd(evflagtguv) = aivlfqcqdv gfdkffqpfo (dzvzmnhdxy ) View more | ||||||
Not Applicable | Triple Negative Breast Cancer Neoadjuvant | 535 | pjysuywevl(ibyqzjoanw): RR = 1.65 (95% CI, 1.15 - 2.37), P-Value = 0.007 View more | Negative | 30 May 2025 | ||